| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/22/2006 | EP1626960A1 Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists |
| 02/22/2006 | EP1626955A1 Captopril derivatives |
| 02/22/2006 | EP1626950A1 Sertraline compositions |
| 02/22/2006 | EP1626913A2 Stabilized pharmaceutical product |
| 02/22/2006 | EP1626739A1 Compositionss for treating infection in cattle and swine |
| 02/22/2006 | EP1626738A2 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 02/22/2006 | EP1626732A2 Means for preventing and treating cellular death and their biological applications |
| 02/22/2006 | EP1626731A2 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 02/22/2006 | EP1626730A1 Method, apparatus, and composition for treating acne |
| 02/22/2006 | EP1626729A2 Compositions and methods for symptomatic relief |
| 02/22/2006 | EP1626728A2 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
| 02/22/2006 | EP1626727A1 Application of 2-cyano-10- (2-methyl-3- (methylamino)- propyl) phenothiazine or a pharmaceutically acceptable salt as medicament |
| 02/22/2006 | EP1626726A2 Use of lornoxicam or lornoxicam analogue compounds |
| 02/22/2006 | EP1626725A2 Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| 02/22/2006 | EP1626724A2 Method and kit for regulation of microvascular tone |
| 02/22/2006 | EP1626723A1 Treatment of bipolar disorders and associated symptoms |
| 02/22/2006 | EP1626722A1 Method for enhancing cognition using ziprasidone |
| 02/22/2006 | EP1626721A2 Carbostyril derivatives and mood stabilizers for treating mood disorders |
| 02/22/2006 | EP1626720A1 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| 02/22/2006 | EP1626718A2 Methods of treating ischemic related conditions |
| 02/22/2006 | EP1626717A2 Benzimidazoles, compositions containing such compounds and methods of use |
| 02/22/2006 | EP1626716A1 Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity |
| 02/22/2006 | EP1626715A1 Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
| 02/22/2006 | EP1626714A2 Diaryl ureas for diseases mediated by pdgfr |
| 02/22/2006 | EP1626713A2 Heterocyclic compounds and uses thereof |
| 02/22/2006 | EP1626712A2 Saururus cernuus compounds that inhibit cellular responses to hypoxia |
| 02/22/2006 | EP1626711A2 Compositions and methods for treating cancer |
| 02/22/2006 | EP1626710A1 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| 02/22/2006 | EP1626709A1 Enantiomeric amphetamine compositions for the treatment of adhd |
| 02/22/2006 | EP1626707A2 Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds |
| 02/22/2006 | EP1626706A2 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals |
| 02/22/2006 | EP1626695A2 Compositions and methods for reducing scar tissue formation |
| 02/22/2006 | EP1626693A2 Ginkgo biloba extract as a treatment for therapeutic- induced neurotoxicity |
| 02/22/2006 | EP1626692A2 Compounds for the treatment of flaviviridae infections |
| 02/22/2006 | EP1626648A2 Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer s disease |
| 02/22/2006 | EP1539672A4 Preparation method of valienamine from acarbose and/or acarbose derivatives using trifluoroacetic acid |
| 02/22/2006 | EP1490029A4 Controlled release drug delivery system of pravastatin |
| 02/22/2006 | EP1456210B1 Pyrazolyl-substituted triazoloquinoxalines |
| 02/22/2006 | EP1441735B1 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| 02/22/2006 | EP1434882A4 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes |
| 02/22/2006 | EP1414812B1 Hydroxamic acid derivatives |
| 02/22/2006 | EP1406622B1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/22/2006 | EP1392704B1 Cephem compounds |
| 02/22/2006 | EP1385856B1 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| 02/22/2006 | EP1385839B1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/22/2006 | EP1384472B1 Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate |
| 02/22/2006 | EP1320300B1 Food supplement |
| 02/22/2006 | EP1251857B1 Pharmaceutical parenteral composition containing a bisphosphonate |
| 02/22/2006 | EP1237874B1 Selective neurokinin antagonists |
| 02/22/2006 | EP1237545B1 Use of stearidonic acid in the manufacture of a medicament for the treatment or prevention of cancer |
| 02/22/2006 | EP1233957B1 Novel amidine derivatives, preparation and use thereof as medicines |
| 02/22/2006 | EP1225881B1 The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction |
| 02/22/2006 | EP1224187B1 Certain alkylene diamine-substituted heterocycles |
| 02/22/2006 | EP1212464B1 Diagnostics and therapeutics for osteoporosis |
| 02/22/2006 | EP1208086B1 Benzamide formulation with histone deacetylase inhibitor activity |
| 02/22/2006 | EP1194584B1 Method for producing oligopolysaccharides |
| 02/22/2006 | EP1093370B1 Pharmaceutical composition for the treatment of diabetes |
| 02/22/2006 | EP1062336B1 Modulators of the function of receptors of the tnf/ngf receptor family |
| 02/22/2006 | EP1051193B1 Anhydrous topical skin preparation comprising ketoconazole |
| 02/22/2006 | EP1040185B1 Neural precursor cells, method for the production and use thereof in neural defect therapy |
| 02/22/2006 | EP1028734B1 Use of specific steady-state r-type calcium channel blockers |
| 02/22/2006 | EP1001781B1 Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases |
| 02/22/2006 | EP0957929B1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/22/2006 | EP0907378B1 Method for the concentration of antibody solutions |
| 02/22/2006 | EP0787206B1 USE OF NEURITE LOCALIZED mRNAs FOR MEDICAL DIAGNOSIS AND THERAPEUTICS |
| 02/22/2006 | EP0766580B1 Compositions of prostacyclin, pge or a nitrovasodilator or combinations thereof for the treatment of diseases of the vascular system |
| 02/22/2006 | EP0549615B1 Sugar modified oligonucleotides that detect and modulate gene expression |
| 02/22/2006 | CN1739030A Diagnosis and prevention of cancer cell invasion |
| 02/22/2006 | CN1738888A Antioxidant, skin preparation for external use, cosmetic and food |
| 02/22/2006 | CN1738832A Ligands |
| 02/22/2006 | CN1738829A New 2',5'-oligoadenylic acid analog |
| 02/22/2006 | CN1738828A Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4''- or 4'-position |
| 02/22/2006 | CN1738827A Novel ampiphilic derivatives of alpha-c-phenyl n-tert-butyl nitrone |
| 02/22/2006 | CN1738825A Thienopyridazinones and their use in modulation of autoimmune disease |
| 02/22/2006 | CN1738821A Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 02/22/2006 | CN1738820A Novel diazabicyclic aryl derivatives |
| 02/22/2006 | CN1738819A 4-oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors |
| 02/22/2006 | CN1738817A Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same. |
| 02/22/2006 | CN1738816A Substituted indolepyridinium as anti-infective compounds |
| 02/22/2006 | CN1738812A Thiophene carboxamides as inhibitors of the enzyme IKK-2 |
| 02/22/2006 | CN1738807A Substituted aralkyl derivatives |
| 02/22/2006 | CN1738806A Oxo-azabicyclic compounds |
| 02/22/2006 | CN1738805A N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as CGRP-antagonists for treating a headache |
| 02/22/2006 | CN1738804A 吡唑化合物 Pyrazole compounds |
| 02/22/2006 | CN1738802A Antibiotics containing borinic acid complexes and methods of use |
| 02/22/2006 | CN1738800A 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 02/22/2006 | CN1738797A Substituted aryl thioureas and related compounds; inhibitors of viral replication |
| 02/22/2006 | CN1738796A Bis-aryl sulfonamides |
| 02/22/2006 | CN1738794A Biguanide and dihydrotriazine derivatives |
| 02/22/2006 | CN1738793A Compounds, compositions and methods |
| 02/22/2006 | CN1738788A Substituted phenyl naphthalenes as estrogenic agents |
| 02/22/2006 | CN1738782A Deuterated catecholamine derivatives and medicaments comprising said compounds |
| 02/22/2006 | CN1738665A Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases |
| 02/22/2006 | CN1738637A DC-SIGN blockers and their use for preventing or treating viral infections. |
| 02/22/2006 | CN1738636A Use of enzyme inhibitors with aminopeptidase N and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases wit |
| 02/22/2006 | CN1738634A Extract of stephaniae sinica diels and methods of using the same |
| 02/22/2006 | CN1738631A Topical composition and methods for treatment of aged or environmentally damaged skin |
| 02/22/2006 | CN1738629A Treatment of benign prostatic hyperplasia using energolytic agents |
| 02/22/2006 | CN1738628A Compositions and methods for combination antiviral therapy |
| 02/22/2006 | CN1738627A Method for inhibition of necrosis induced by neurotrophin |